Doliprane is probably the best-selling drug in France and it is possible that it will become an American product, because negotiations between Sanofi and an American investment fund are ongoing.
Doliprane is the medicine the best seller in France and it is possible that in the coming days, it will become an American product. Indeed, Sanofi and an American investment fund are in full negotiations. However, these arrangements raise the question of health sovereigntya commitment repeated by the President of the Republic since the health crisis of the Coronavirus, which remains a reality, because the wearing a mask is always recommended. In June 2023, the Head of State said that it is important to continue the transfer of the finished product or the raw material to ensure the supply stock.
Sale of Doliprane: health sovereignty in danger?
For health sovereignty
It is therefore in the name of it health sovereignty that parliamentarians from all sides invite our government to block this session which according to them is a matter of national security. But what does this hide? sale from Doliprane to the Americans? This sale is one of the government’s burning issues. Indeed, this redemption is this controversy around the drug gives the impression that France is abandoning its independence. The French do not ask what the government can do, but rather what it wants to do.
Remembering the facts
On the one hand we have Sanofi, one of the pharmaceutical giantsand Opel, you know subsidiary specialized in the sale of Maalox, Lysopaïne and of course Doliprane, this medication that has known the shortage the past years. These are the medications you can get without a prescription. Besides, we all have them in our closets. On the other hand we have CD&R, Clayton Dubilier And Rice, a American background who won auction to become the owner of Opella. Between the two parties, we find the government that arbitrates a surrender which is worth more than 15 billion euros.
So many jobs at stake
So this is a real debate that we have here: we should welcome a industrial investment foreigner of such stature in our country? Or should we worry about losing our sovereignty in the Hi ? The Opella subsidiary has 13 production sites, 11,000 employees and coverage in around 150 countries. Its headquarters are located in France. Emmanuel Macron has always insisted on French sovereignty regarding health. Will it continue? Last Monday, two ministers raided a site of the pharmaceutical giant in Normandy for a mining operation.
Sale of Opel to the Americans: government conditions
What the government wants
U oppositions mobilized after the announcement of the sale and we heard about it fears of shortage at the global level and health sovereignty. All PS deputies signed last weekend The Sunday Tribunea call to block the redemption. The government, for its part, supports the transfer, but sets its conditions. First, the government wants the chair to remain French. He also wants the works to be preserved and sustainable factories. When it comes to providing, the executive wants guarantees. Precisely on Doliprane, one of the drugs accused of containing a toxic substance.
The sale may be blocked
Are American buyers ready to give and respect all these conditions ? Under the control procedure foreign investments also called Montebourg’s law, the government can effectively block the sale. Indeed, this law authorizes a minister to intervene if the purchaser is a foreigner, this is the case, if it is a sensitive subject such as health, this is also the case. As a result, Antoine Armand, the current Minister of the Economy, announced that the procedure will be initiated. However, Audrey Duval guarantees the French the presence of Doliprane in pharmacies if the sales agreement is signed, reports In the evening.
The deal goes bad goes bad
The real problem here is that there were precedents that took a bad turn. Indeed, in 2014, General Electric acquired the energy activities of Alstom. Before the sale, the buyers, Americans, had taken theengagement to create many jobs, unfortunately, this commitment was not respected and only thirty jobs were created. In addition, only 50 million euros had been paid by General Electric to a reindustrialization fund. There are many other such examples.